Johnson & Johnson·Healthcare

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, launching a global program to develop an open surgical intelligence network— establishing Abu Dhabi as the first node in a global infrastructure designed to accelerate artificial intelligence (AI) innovation for every stage of the surgery experience. Integrating Johnson & Johnson's Polyphonic™ o.

Johnson & Johnson's nipocalimab has won approval in China, the U.S. drugmaker said on its WeChat social media account Thursday.

Paychecks stop. Bonuses get cut.

Johnson & Johnson offers a superior return/risk profile versus Pfizer, driven by consistency and operational stability. PFE's far lower valuation (FWD P/E 8.55x, PEGY 0.97x) and far higher yield (6.79%) are certainly attractive. But JNJ's 63-year streak of dividend growth, lower payout ratio (48.46%), ongoing buybacks, and stable inventory all point to far superior consistency.

A $40,000 annual income is often enough for a 62-year-old retiree living modestly while bridging the five years until full Social Security benefits begin at 67. The challenge is generating that income entirely from dividends without selling shares or steadily drawing down principal. The core equation is simple: divide the target income by the portfolio's yield... How Much Do You Really Need Invested to Replace a $40,000 Salary at 62 and Bridge the Five Years Until Social Security at 67?

ExxonMobil, Johnson and Johnson, and Coca-Cola are safe stocks to buy and forget.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Healthcare
Drug Manufacturers - General
138,100
1943-01-02
0.26